PDS0101 (Versamune®-HPV)
Recurrent/Metastatic HPV16+ Head & Neck Cancer
Key Facts
Indication
Recurrent/Metastatic HPV16+ Head & Neck Cancer
Phase
Phase 3
Status
Active
Company
About PDS Biotechnology
PDS Biotech is a clinical-stage company developing next-generation immunotherapies based on its proprietary Versamune® T-cell activating platform and PDS01ADC tumor-targeted IL-12. The company has generated compelling Phase 2 data in HPV-positive head and neck cancer, demonstrating significant tumor shrinkage and extended survival, and has now initiated a pivotal Phase 3 trial. Its strategy centers on advancing its lead asset, PDS0101, towards commercialization in HPV-associated cancers while exploring platform applications in other cancers and infectious diseases through strategic partnerships.
View full company profile